Millington Securities’s Royalty Pharma RPRX Stock Holding History

Millington Securities’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$281K	Buy	+5,857	New	+$257K	0.08%	246

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millington Securities's RPRX Position: Q1 2026 in Review

Millington Securities opened a new position in Royalty Pharma (RPRX) in Q1 2026: 5,857 shares worth $281K. The stake represents 0.08% of the portfolio and ranks #246 among its holdings.

587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Millington Securities held 5,857 shares of Royalty Pharma worth $281K as of Q1 2026.
Royalty Pharma was a new Millington Securities position in Q1 2026.
Royalty Pharma made up 0.08% of Millington Securities's portfolio in Q1 2026, its #246 holding.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Millington Securities's 13F filing for Q1 2026, filed 15 Jul 2026.